Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2620472 | 0.87 | KMT2A (0.32) | KMT2AKDM4EALDH1A1HPGDATM | |
| SCHEMBL13758719 | 0.84 | — | — | |
| SCHEMBL2107478 | 0.84 | NR1I2 (0.31) | KDM4EATM | |
| SCHEMBL2107479 | 0.84 | NR1I2 (0.31) | KDM4EATM | |
| SCHEMBL2620386 | 0.82 | TP53 (0.33) | KMT2AKDM4EALDH1A1HPGDATM | |
| SCHEMBL2620388 | 0.81 | KDM4E (0.33) | KMT2AKDM4EALDH1A1HPGDATM | |
| SCHEMBL14214795 | 0.81 | TP53 (0.32) | KMT2AKDM4EALDH1A1HPGDATM | |
| SCHEMBL12464241 | 0.72 | KDM4E (0.38) | KMT2AKDM4EALDH1A1HPGDATM | |
| SCHEMBL2107515 | 0.71 | ALDH1A1 (0.36) | KMT2AKDM4EALDH1A1HPGDATM | |
| SCHEMBL12464522 | 0.71 | KMT2A (0.37) | KMT2AKDM4EALDH1A1HPGDATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158675-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-04-17 | — | — | US | disclosed |
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093775-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | ZC3HAV1, YBX1, HAX1 | KMT2A 3282/4885KDM4E 2984/4885ALDH1A1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.